Friday Satellite Symposia
Friday Satellite Symposia (FSS) are industry-supported, CME-accredited symposia that are offered the day preceding the American Society of Hematology (ASH) annual meeting. These sessions are not part of the official ASH annual meeting program and are planned solely by the organizing company.
ASH appreciates its corporate and nonprofit partners for their participation in FSS. The Society values its partnerships and the supportive role that members of this community play in an effort to provide hematologists with quality educational programs. For more information, please review the 2025 FSS guidelines or contact Kelly Cade, Grants and Satellite Symposia Manager, Consultant, at [email protected].
Advances in Targeting Angiogenesis and Managing Severe Anemia in Vascular Bleeding Disorders:Hereditary Hemorrhagic Telangiectasia, Von Willebrand Disease, and Beyond
This program is supported by Pharmacosmos Therapeutics Inc. and Alnylam Pharmaceuticals.
7:00 a.m. - 10:00 a.m. Eastern time
OCCC - W224ABEF
Hematologists in both community and academic practice are increasingly being called upon to use antiangiogenic treatments to treat patients with inherited and acquired vascular bleeding disorders, including hereditary hemorrhagic telangiectasia (HHT), von Willebrand disease, acquired von Willebrand syndrome, and others. This symposium will discuss the role of angiogenesis in these bleeding disorders, how to optimally manage this bleeding with anti-angiogenic agents such as bevacizumab, pomalidomide, and pazopanib, and how to properly manage the complex and difficult chronic, severe iron deficiency anemia that complicates the course of these patients. Current and future potential antiangiogenic and coagulation-based treatments will be discussed by international leaders in the field.
Chair:
Hanny Al-Samkari, M.D.
Massachusetts General Hospital
Speakers:
Hanny Al-Samkari, M.D.
Massachusetts General Hospital
Magdalena Lewandowska, MD
Innovative Hematology
Allyson Pishko, MD
University of Pennsylvania
Jenny Zhou, MD
University of California, San Diego
Contact:
Hellen Tecle
, Cure HHT
Email: [email protected]
Aligning Discovery With Clinical Practice: Applying Expert Consensus Guidelines To Improve Patient Outcomes in CLL/SLL
This program is supported by AstraZeneca and Lilly. Provided by the National Comprehensive Cancer Network (NCCN) in collaboration with Clinical Care Options, LLC.
7:00 a.m. - 10:00 a.m. Eastern time
Virtual Symposium Only
This session will be live streamed on hematology.org during the scheduled time.
Join NCCN and CCO for an engaging virtual symposium focused on the real-world application of NCCN guideline–recommended therapies for patients with chronic lymphocytic leukemia (CLL). This dynamic event features expert panel discussions and interactive case challenges to explore the latest treatment strategies across frontline and relapsed/refractory settings. Gain practical insights into selecting and sequencing covalent and noncovalent BTK inhibitors, BCL2 inhibitors, CAR T-cell therapy, incorporating molecular testing, and managing adverse events to support adherence. The program also delves into emerging therapies—including BTK degraders and bispecific antibodies —offering guidance on how to integrate these innovations into clinical practice through clinical trials. Engage directly with leading experts through live Q&A and learn how to deliver personalized, evidence-aligned CLL care.
Chair:
Sameer A. Parikh, MD
Mayo Clinic
Speakers:
Matthew J. Cortese, MD, MPH
Roswell Park Comprehensive Cancer Center
Brian Hill
Cleveland Clinic Taussig Cancer Institute
Contact:
Melanie Moletzsky
, The National Comprehensive Cancer Network
Email: [email protected]
Beyond Chemotherapy: Patient Voices and Expert Insights on Using Precision Therapies to Enhance Personalized Care of Follicular Lymphoma
This program is supported by AstraZeneca, Genentech, a member of the Roche Group, Incyte Corporation, Novartis Pharmaceuticals Corporation, and Regeneron Pharmaceuticals, Inc. Provided by Clinical Care Options, LLC in partnership with the Follicular Lymphoma Foundation.
7:00 a.m. - 10:00 a.m. Eastern time
Hyatt - Regency Ballroom R
This session will be live streamed on hematology.org during the scheduled time.
Join CCO and The Follicular Lymphoma Foundation for an innovative symposium spotlighting the latest advancements in relapsed/refractory (R/R) follicular lymphoma (FL) care. This dynamic session blends global patient survey insights, expert-led case discussions, and interactive polling to explore precision, chemotherapy-free strategies. Learn how to optimize the use of bispecific antibodies, CAR T-cell therapy, and novel targeted agents such as tazemetostat, tafasitamab, and BTK inhibitors. Engage directly with expert faculty in Q&A and townhall forums as they share practical guidance on therapy selection, sequencing, safety monitoring, and real-world implementation. Stay ahead of the curve with highlights of emerging clinical trial data and future directions in FL management. This symposium will challenge your clinical perspective, deepen your understanding of the shifting FL landscape, and empower you to deliver more personalized, evidence-informed care.
Chair:
Laurie Sehn, MD
BC Cancer
Speakers:
Peter Martin, FRCPC, MD, MS
Weill Cornell Medicine
Gilles Salles, MD, PhD
Memorial Sloan Kettering Cancer Center
Mitchell R. Smith
The Follicular Lymphoma Foundation
Contact:
Julie Dodds
, The Follicular Lymphoma Foundation
Email: [email protected]
Registration for Virtual Program
Consensus or Controversy? Clinical Investigators Provide Perspectives on the Current and Future Management of Patients with Acute Myeloid Leukemia
This program is supported by educational grants from AbbVie Inc., Astellas, Daiichi Sankyo Inc., Kura Oncology, and Rigel Pharmaceuticals Inc.
7:00 a.m. - 10:00 a.m. Eastern time
Hyatt - Regency TUV
This session will be live streamed on hematology.org during the scheduled time.
This 2-hour CME-accredited activity – offered to both in-person and virtual attendees – will focus on the management of patients with acute myeloid leukemia (AML). Five clinical investigators will serve as the faculty and Dr Neil Love, RTP president, will moderate. RTP will also recruit 3 additional consulting clinical investigators who in addition to the faculty will complete a survey focused on controversial questions related to the management of AML. The responses from all 8 investigators will be graphically depicted and presented at the meeting to augment discussion and foster debate. The meeting agenda will be divided into 5 modules, each consisting of a review of survey results followed by a formal presentation of relevant research. Attendees will be able to submit questions and cases of their own, a number of which will be incorporated into the discussion. Pre-registration is advised as seating is limited.
Chair:
Neil Love, MD
Research To Practice
Speakers:
Harry Erba, MD, PhD
Duke University School of Medicine
Amir T. Fathi, MD
Massachusetts General Hospital
Tara L Lin
University of Kansas Medical Center
Alexander Perl, MD
University of Pennsylvania
Eytan Stein, MD
Memorial Sloan Kettering Cancer Center
Contact:
Sylvia Eriksen
, Research To Practice
Email: [email protected]
Registration for Virtual Program
Many Roads to Myeloma Remission: Making Sequential Choices With BCMA and non-BCMA Immunotherapies
This program is supported by independent medical education grants from GSK, Johnson and Johnson and Regeneron Pharmaceuticals, Inc. This CME/MOC/EBAH/AAPA activity is provided by PVI, PeerView Institute for Medical Education and developed with our educational partner, the HealthTree Foundation for Multiple Myeloma.
7:00 a.m. - 10:00 a.m. Eastern time
Hyatt - Plaza Int'l HIJK
This session will be live streamed on hematology.org and the ASH Virtual Meeting Platform during the scheduled time.
Therapeutic innovation in relapsed/refractory multiple myeloma (RRMM) isn’t just evolving—it’s accelerating. Central to these innovations is: 1) the expansion of B-cell maturation antigen (BCMA)-targeting CAR-T therapy into earlier lines of treatment, and 2) the increasing availability of off-the-shelf immunotherapies, including antibody-drug conjugates (ADCs) and bispecific antibodies. The innovation doesn’t stop at BCMA—novel targets like GPRC5D and FcRH5 are paving new therapeutic roads for disease progression after BCMA-directed therapy. Are you prepared to utilize this expanding therapeutic arsenal to personalize treatment plans for patients with RRMM?
Learn about optimal sequential choices with BCMA and non-BCMA immunotherapies. Using real-world patient examples, expert panelists will provide guidance on the early use of CAR-T therapy, considerations for off-the-shelf BCMA and non-BCMA immunotherapies across diverse MM settings, and insights on the clinical adoption of these therapies.
Chair:
Sagar Lonial, MD, FACP
Winship Cancer Institute, Emory University School of Medicine
Speakers:
Hans C Lee, MD
Sarah Cannon Research Institute
Krina Patel, MD, MSc
The University of Texas MD Anderson Cancer Center
Contact:
Amanda Loeber
, PVI, PeerView Institute for Medical Education
Email: [email protected]
Registration for Virtual Program
MASTER MDS for Enhanced Patient Care: Modern Advances with STandard and Emerging, Risk-adapted Treatment
This program is supported by educational grants from Ascentage Pharma, Bristol Myers Squibb and Geron. This CME/MOC/EBAH/AAPA activity is provided by PVI, PeerView Institute for Medical Education and developed with our educational partner, the HealthTree Foundation for Myelodysplastic Syndromes.
7:00 a.m. - 10:00 a.m. Eastern time
Hyatt - Plaza Int'l DEFG
This session will be live streamed on hematology.org during the scheduled time.
This Clinical Consults event will demonstrate how clinicians can confidently tailor myelodysplastic syndromes (MDS) care based on clinical trial data, guideline recommendations, and a comprehensive assessment of patient- and disease-related factors such as symptoms, molecular features, and care preferences. Our expert faculty will combine conversational case-based teaching, breaking evidence, and insights on the unique experiences of people living with MDS (provided by the HealthTree Foundation for Myelodysplastic Syndromes) – all with the goal of offering in-depth, patient-centric guidance.
Chair:
Guillermo Garcia-Manero, MD
The University of Texas MD Anderson Cancer Center
Speakers:
Maria Diez-Campelo, MD, PhD
Hospital Clínico Universitario de Salamanca
Sangeetha Venugopal, MD, MS
Sylvester Comprehensive Cancer Center, University of Miami
Contact:
Amanda Loeber
, PVI, PeerView Institute for Medical Education
Email: [email protected]
Registration for Virtual Program
Menin Masters for AML Care: Guidance on Integrating Menin Inhibitor Regimens & Boosting Efficacy in Challenging AML Subtypes
This program is supported by independent educational grants from Johnson and Johnson, Kura Oncology, Inc., and Syndax. This CME/EBAH/AAPA/IPCE activity is provided by PVI, PeerView Institute for Medical Education and developed with our educational partner, the HealthTree Foundation for Acute Myeloid Leukemia.
7:00 a.m. - 10:00 a.m. Eastern time
OCCC - Valencia Room W415D
This session will be live streamed on hematology.org during the scheduled time.
Despite nearly a decade of therapeutic advances in acute myeloid leukemia (AML), challenges remain for patients with difficult-to-treat presentations, including KMT2A rearrangements or progressive NPM1-mutated disease. Menin inhibitors have emerged as a precision medicine approach to address these unmet needs, with accumulating evidence increasingly supporting their use as monotherapy and in potent combinations with standard-of-care platforms. These developments have raised questions on best practices for integrating this novel class into patient care.
Join PeerView Live and the Health Tree Foundation at the 2025 ASH Annual Meeting and Exposition or online for expert insight on ongoing challenges in poor-prognosis AML settings and the role of menin inhibitors for KMT2Ar/NPM1m AML. Concise lectures will inform case-based discussions on the present and future of menin inhibitor–based treatment in AML, including in innovative combinations and the first-line setting.
Chair:
David Sallman, MD
H. Lee Moffitt Cancer Center
Speakers:
Tapan Kadia, MD
The University of Texas MD Anderson Cancer Center
Dr. Emma Searle, MBChB, PhD
The Christie NHS Foundation Trust, University of Manchester
Contact:
Amanda Loeber
, PVI, PeerView Institute for Medical Education
Email: [email protected]
Registration for Virtual Program
Momentum in MDS: Making Progress and Shaping a Better Future
This program is supported by independent educational grants from Agios Pharmaceuticals, Bristol Myers Squibb, Geron Corporation, Rigel Pharmaceuticals, and Taiho Oncology, Inc. This program is provided by The Myeolodysplastic Syndromes Foundation, Inc. in partnership with AKH Inc., Advancing Knowledge in Healthcare.
7:00 a.m. - 10:00 a.m. Eastern time
OCCC - Tangerine Ballroom F2
Recently, significant progress has been made in understanding the biology, genetics, and pathogenesis of MDS. These advances have led to meaningful developments in diagnosis, risk-stratification, and disease management—insights that will be reflected in the new international treatment guidelines, set to be presented and published by a leading global consortium of MDS experts.
Among the evolving topics in the field is the role of morphology in modern medicine. This issue will be explored in depth along with the implications of germline mutations in MDS patients and how this knowledge necessitates a reassessment of current clinical approaches.
The continued need for more effective therapies has also inspired the inclusion of a dedicated session on drug development, with a specific focus on the MDS pipeline.
The program will also feature a patient-centered discussion to bridge the gap between scientific advancements and the lived experience of those navigating MDS in real-world settings.
Chairs:
Moshe Mittelman, MD
Tel-Aviv Sourasky Medical Center
Valeria Santini, MD
AOU Careggi-University of Florence
Speakers:
Rafael Bejar, MD,PhD
University of California San Diego
Rena Buckstein, MD, FRCPC
Sunnybrook Health Sciences Centre
Carmelo Gurnari, MD,PhD
University of Tor Vergata
Robert P Hasserjian, MD
Massachusetts General Hospital and Harvard Medical School
Moshe Mittelman, MD
Tel-Aviv Sourasky Medical Center
Valeria Santini, MD
AOU Careggi-University of Florence
David Peter Steensma, MD
Ajax Therapeutics
Arjan Van de Loosdrecht, MD, PhD
VU University Medical Center
Contact:
Lea Harrison
, MDS Foundation, Inc.
Email: [email protected]
Registration for Virtual Program
Moving Forward in B-ALL: Insights on Modern and Emerging Standards With Off-the-Shelf Bispecific Antibodies
This program is supported by an independent educational grant from AstraZeneca. This CME/MOC/EBAH activity is provided by PVI, PeerView Institute for Medical Education and developed with our educational partner, the HealthTree Foundation for Acute Lymphoblastic Leukemia.
7:00 a.m. - 10:00 a.m. Eastern time
OCCC - Valencia Room W415BC
This session will be live streamed on hematology.org and the ASH Virtual Meeting Platform during the scheduled time.
Modern treatment of B-ALL reflects the ongoing evolution of precision medicine and immuno-oncology, moving beyond traditional chemotherapy and HCT to include frontline and sequential use of bispecific TCEs. Alongside established bispecifics, emerging CD19 x CD3 TCEs are poised to make inroads in R/R ALL, offering additional off-the-shelf options for use in the clinic. In light of this innovation, how can clinicians help move the field of immunotherapy forward in ALL and upgrade current treatment protocols based on the latest evidence
In collaboration with HealthTree Foundation for ALL, this PeerView initiative, held during the ASH Annual Meeting, will provide expert perspectives on modern clinical standards in modern ALL care while preparing clinicians for future innovation with TCE strategies. Throughout the case-based workshops, the expert faculty will cover the role of TCEs, MRD monitoring, evidence supporting newer bispecifics, and practical considerations when implementing TCEs.
Chair:
Nicola Gökbuget, MD
University Hospital
Speakers:
Ibrahim Aldoss, MD
City of Hope National Medical Center
Nicholas J. Short, MD
The University of Texas MD Anderson Cancer Center
Contact:
Amanda Loeber
, PVI, PeerView Institute for Medical Education
Email: [email protected]
Registration for Virtual Program
Off the Shelf and in the Clinic for NHL: Leveraging Bispecific Antibody Strategies in DLBCL, FL, and Beyond
This program is supported by independent educational grants from AstraZeneca and Regeneron Pharmaceuticals, Inc. This CME/MOC/EBAH/AAPA activity is provided by PVI, PeerView Institute for Medical Education and developed with our educational partner, the HealthTree Foundation for Non-Hodgkin Lymphoma.
7:00 a.m. - 10:00 a.m. Eastern time
OCCC - Valencia Room W415A
This session will be live streamed on hematology.org and the ASH Virtual Meeting Platform during the scheduled time.
Bispecific antibodies have emerged as critical tools in the treatment arsenal for aggressive and indolent non-Hodgkin lymphoma (NHL), including diffuse large B-cell lymphoma, mantle cell lymphoma, and follicular lymphoma. These unique off-the-shelf immunotherapy options offer the opportunity to improve patient outcomes but also highlight the need for strategies to effectively integrate this transformative class of agents into patient care.
In collaboration with HealthTree Foundation for NHL, PeerView has prepared this expert-led case-based Workshops symposium designed to model team-based care solutions for integrating bispecifics into clinical practice. Each Workshop will include high-level seminar segments covering the latest clinical evidence on modern and emerging CD20 x CD3 bispecific antibodies in diverse NHL subtypes. Throughout, the panel will address practical aspects of care such as step-up dosing, inpatient/outpatient administration, AE management, and supportive care planning. Hear the experts discuss how to bring off-the-shelf bispecifics into your clinic and offer optimal care for your patients with NHL.
Chair:
Prof. Dr. Max S Topp, MD
Universitätsklinikum Würzburg
Speakers:
Sameh Gaballa, MD
H. Lee Moffitt Cancer Center
Deepa Jagadeesh, MD, MPH
Cleveland Clinic
Contact:
Amanda Loeber
, PVI, PeerView Institute for Medical Education
Email: [email protected]
Registration for Virtual Program
Paroxysmal Nocturnal Hemoglobinuria: What we have learned from the introduction of new therapies
This program is supported by independent educational grants from AstraZeneca, Novartis, Roche, Sobi and Apellis.
7:00 a.m. - 10:00 a.m. Eastern time
OCCC - Tangerine Ballroom F1
This session is in-person and does not have a virtual component. Please contact the Managing Company Contact with questions.
The 2025 Symposium will address the impact of diagnostic and therapeutic advances over the past 143 years on recent advances in the management of patients with this rare but fascinating acquired genetic disorder involving hematopoietic stem cells. The program combines a historical perspective along with recent scientific data on the impact of therapies targeting several complement factors, proximal, distal; and both. The program will discuss the new scenario of of broad treatment options, as well as ongoing scientific projects of the IPIG, such as the work underway to modernize diagnostic and therapeutic guidelines of novel guidelines and the development of an International, academic disease registry. The availability of appropriate diagnostics and therapies in different parts of the world.
Chairs:
Morag Griffin, FRCPath, MBChB, MRCP
Leeds Teaching Hospital NHS
Phillip Scheinberg, MD
David Araten, MD
NYU Langone
Speakers:
Louise Marianne Arnold, ACP, MSc
Leeds Teaching Hospital NHS
Camilla Frieri
AORN San Giuseppe Moscati Avellino
Xiaojun Huang
Peking University People’s Hospital
Bhavisha Patel
NIH
Daniel Payne
Leeds Teaching Hospital NHS
Regis Peffault De Latour, MD
Saint-Louis Hospital
Antonio M. Risitano, MD, PhD
AORN San Giuseppe Moscati Avellino
Jeff Szer, BMedSc, MB, BS
AORN San Giuseppe Moscati Avellino
Contact:
Emma Erickson
Email: [email protected]
Dawn McKnight
, AORN San Giuseppe Moscati Avellino
Email: [email protected]
Pathways to Personalized Remission in CLL: Leveraging Targeted Standards & Next-Gen Advances for Upfront and Sequential Care
This program is supported by independent educational grants from AstraZeneca, BeOne Medicines, and Lilly. This CME/MOC/EBAH/AAPA/IPCE activity is provided by PVI, PeerView Institute for Medical Education and developed with our educational partner, CLL Society.
7:00 a.m. - 10:00 a.m. Eastern time
Hyatt - Orlando Ballroom
This session will be live streamed on hematology.org and the ASH Virtual Meeting Platform during the scheduled time.
The modern CLL care pathway now centers on the continuous use of covalent BTK inhibitors (BTKi) and time-limited BCL2 inhibitor (BCL2i) regimens. New time-limited BTKi-BCL2i combinations have emerged to offer innovative standards for treatment-naïve patients, while in the relapsed/refractory setting, non-covalent BTKis, CAR-T cell therapy, and next-generation agents have emerged as standards of care in their own right or in potentially novel ways (such as with BTK degraders) to attack CLL.
In collaboration with CLL Society, this PeerView expert-led activity during the 67th ASH Annual Meeting and Exposition will cover modern CLL pathways to remission through a series of interactive, case-based workshops focused on real-world challenges in CLL care. Throughout, the panelists will model team-based strategies for improving outcomes with continuous or time-limited therapy in frontline settings, while providing insights on the evidence- and guideline-based use of targeted therapy for sequential care in relapsed/refractory CLL.
Chair:
John Gribben, MD, DSc, FRCP, FMedSci, FRCPath
Barts Cancer Institute, Barts and The London School of Medicine, Queen Mary, University of London
Speakers:
Nicole Lamanna, MD
Herbert Irving Comprehensive Cancer Center New York-Presbyterian/Columbia University Medical Center
Meghan C. Thompson, MD
Memorial Sloan Kettering Cancer Center
William G. Wierda, MD, PhD
The University of Texas MD Anderson Cancer Center
Contact:
Amanda Loeber
, PVI, PeerView Institute for Medical Education
Email: [email protected]
Registration for Virtual Program
Reaching Clinical Trial Excellence: Practical Strategies for Achieving Generalizable and Transportable Data
This program is supported by Indy Hematology Education Inc.
7:00 a.m. - 10:00 a.m. Eastern time
OCCC - W224CDGH
This session is in-person and does not have a virtual component. Please contact the Managing Company Contact with questions.
This workshop will bring together experts in clinical research, policy, biostatistics, and patient advocacy to address the persistent underrepresentation of diverse populations in clinical trials. Through a multi-session format, the event will explore systemic, provider-level, and patient-level barriers to equitable trial access and participation.
The first session will focus on structural solutions, highlighting how governance, industry partnerships, legal frameworks, and editorial policies can be aligned to drive inclusive research design and dissemination. Participants will gain insight into actionable strategies to embed equity at the institutional level.
The second session will center on the provider’s role in promoting representation. Speakers will examine how to educate, recruit, and retain investigators committed to equitable research, as well as how biostatistical tools can identify and correct bias within trial design and execution.
Finally, the third session will explore patient-level barriers to trial access, including restrictive eligibility criteria and historical mistrust. Presenters will share approaches to designing more inclusive protocols, building trust with underserved communities, and elevating the role of patient advocates.
Together, these sessions will provide a comprehensive framework for creating more representative, ethical, and effective clinical research that leads to better outcomes for all populations.
Chairs:
Andrew Hantel, MD, MPH
Assistant Professor of Medicine; Harvard Medical School
Karen Winkfield
Vanderbilt University Medical Center
Speakers:
Maya Nicole Birhiray, M.S.
Medical Student; Indiana University School of Medicine
Carmen Guerra, MSCE, FACP
University of Pennsylvania: Perelman School of Medicine
Catherine Lai, MD, MPH
Associate Professor of Clinical Medicine and Physician Leader of the Leukemia Clinical Research Unit; University of Pennsylvania’s Perelman Center for Advanced Medicine
Medha Makhlouf, JD
Penn State Dickinson Law
Alan Mast, MD, Ph.D.
Versiti Blood Research Institute
Chadi Nabhan, MBA, FACP
Ryght AI, Inc
Sam Ranger, M.S.
Indy Hematology Education Inc.
Nikhil Thaker, MHA, MBA, PMP, CMQ, FABS, DABR, DABPM
AI in Precision Oncology
Karriem Watson, DHSc, MS, MPH
Mile Square Health Center
Contact:
Sam Ranger
, Indy Hematology Education Inc.
Email: [email protected]
Redrawing Frontlines in MCL: The Upfront Expansion of BTKi Options & Modern Clinical Decision-making in Newly Diagnosed Disease
This program is supported by an independent educational grant from AstraZeneca. This CME/MOC/EBAH/AAPA activity is provided by PVI, PeerView Institute for Medical Education and developed with our educational partner, the HealthTree Foundation for Mantle Cell Lymphoma.
7:00 a.m. - 10:00 a.m. Eastern time
Hyatt - Regency Ballroom S
This session will be live streamed on hematology.org and the ASH Virtual Meeting Platform during the scheduled time.
Bruton’s tyrosine kinase inhibitors (BTKi) are reshaping mantle cell lymphoma (MCL) treatment. This began with the second-line use of BTKi following progression on chemoimmunotherapy (CIT) and now includes the 1L use of BTKi regimens based on evidence that combinations with CIT can improve outcomes. Simultaneously, BTKi-based chemo-free regimens have been effective in frail, newly diagnosed patients, signaling another potential change in 1L treatment. This introduces new opportunities for BTKi-based frontline combinations to enhance outcomes and quality of life.
In collaboration with HealthTree Foundation for Mantle Cell Lymphoma, PeerView’s Clinical Consults symposium will link case-based teaching with lectures to demonstrate how the latest evidence on 1L BTKi platforms is impacting decision-making for different MCL presentations and patient cohorts. Experts will provide insights on using BTKi-CIT regimens in transplant and non-transplant settings and guidance on using BTKi options as part of a chemo-free strategy.
Chair:
Martin Dreyling, MD, PhD
Ludwig-Maximilian-University Munich
Speakers:
Kami Maddocks, MD
The Ohio State University Comprehensive Cancer Center
Christine Ryan, MD
Harvard Medical School, Dana-Farber Cancer Institute
Contact:
Amanda Loeber
, PVI, PeerView Institute for Medical Education
Email: [email protected]
Registration for Virtual Program
Rising to the Graft-vs-Host Disease Challenge: Progress in Treatment and Post-HCT Outcomes Across Hematologic Cancers
This program is supported by independent educational grants from Incyte Corporation, Mesoblast Inc, Orca Bio, and Sanofi US. This CME/MOC/EBAH/AAPA activity is provided by PVI, PeerView Institute for Medical Education and developed with our educational partner, the Blood and Marrow Transplant Information Network.
7:00 a.m. - 10:00 a.m. Eastern time
OCCC - W331
This session will be live streamed on hematology.org and the ASH Virtual Meeting Platform during the scheduled time.
This Clinical Consults activity, developed in partnership with BMT InfoNet, will provide learners with a comprehensive overview of innovative strategies for managing graft-vs-host disease (GVHD). Our expert faculty panel will explore new targeted and cellular-based therapies that aim to reduce nonrelapse mortality while preserving the graft-versus-tumor effect. Through real-world scenarios and expert-led discussions, attendees will gain insights on modern targeted options (such as JAK and ROCK inhibitors), as well as the emerging role of precision T-cell and other cell-based therapies. During the event, experts will also highlight resources that can be used to engage with patients preparing for allogeneic hematopoietic cell transplantation who are at risk for GVHD. Be sure you are equipped to rise to the GVHD challenge.
Chair:
Zachariah Defilipp, MD
Massachusetts General Hospital
Speakers:
Betty K. Hamilton
Cleveland Clinic
Amandeep Salhotra
City of Hope National Medical Center
Contact:
Amanda Loeber
, PVI, PeerView Institute for Medical Education
Email: [email protected]
Registration for Virtual Program
Steady Progress in Multiple Myeloma: Applying New Data and Updated Guidelines Throughout Treatment
This program is supported by AbbVie and GSK, Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC and Karyopharm Therapeutics. Provided by the National Comprehensive Cancer Network (NCCN) in collaboration with Clinical Care Options, LLC.
7:00 a.m. - 10:00 a.m. Eastern time
Hyatt - Regency Ballroom OPQ
This session will be live streamed on hematology.org during the scheduled time.
Join CCO for an engaging symposium focused on the real-world application of NCCN guideline–recommended therapies for patients with multiple myeloma (MM). This dynamic event combines expert panel discussions and interactive case challenges to explore evolving treatment strategies across the MM continuum—from smoldering and newly diagnosed disease to relapsed/refractory settings. Gain practical insights into selecting and sequencing therapies such as triplet and quadruplet regimens, bispecific antibodies, and CAR T-cell products, while managing associated toxicities and coordinating care across practice settings. The program also addresses disparities in access to care and strategies to promote equitable treatment delivery. Engage directly with leading MM experts through live polling and Q&A sessions, apply the latest evidence to real-world cases, and preview key NCCN updates and ASH 2025 data. This symposium will deepen your understanding of guideline-aligned MM care, challenge your clinical decision-making, and empower you to optimize outcomes for diverse patient populations.
Chair:
Thomas Martin, MD
Helen Diller Family Comprehensive Cancer Center
Speakers:
Carol Huff, MD
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Adriana Rossi
Tisch Cancer Institute
Contact:
Melanie Moletzsky
, The National Comprehensive Cancer Network
Email: [email protected]
Registration for Virtual Program
‘Four’ Every Patient: Maximizing Outcomes in Newly Diagnosed Multiple Myeloma Care with Anti-CD38 Monoclonal Antibody-Based Quadruplet Therapies
This program is supported by an educational grant from Sanofi. Provided by Answers in CME.
11:00 a.m. - 2:00 p.m. Eastern time
OCCC - Valencia Room W415D
This session will be live streamed on hematology.org during the scheduled time.
Quadruplet regimens powered by anti-CD38 antibodies have transformed the treatment landscape in newly diagnosed multiple myeloma. Are you confident you’re using these game-changing therapies to their full potential? This interactive 60-minute symposium brings you face-to-face with two leading multiple myeloma experts—Paul Richardson, MD, and Caitlin Costello, MD—who will decode the latest phase 3 trial data, review strategies for tackling side effects, and offer insights on personalizing therapy. Participate in the live Q&A to challenge the faculty with your real-world patient scenarios and sharpen your insight into NDMM therapies. Don’t just keep up with the cutting edge—be part of it. Claim your seat at the next evolution in multiple myeloma care!
Speakers:
Caitlin Costello, MD
University of California, San Diego
Paul G. Richardson, MD
Harvard Medical School, Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute
Contact:
Kaitlyn Hoster
, Answers in CME
Email: [email protected]
Registration for Virtual Program
A Master Class in CP-CML: New Agents, Treatment Goals, and Clinical Challenges
This program is supported by Novartis Pharmaceuticals Corporation. Provided by Clinical Care Options, LLC.
11:00 a.m. - 2:00 p.m. Eastern time
Hyatt - Regency Ballroom R
This session will be live streamed on hematology.org during the scheduled time.
Join CCO for this engaging symposium reviewing the latest advancements in chronic phase chronic myeloid leukemia (CP-CML) management. This activity will feature experts discussing cases illustrating clinical applications of the latest data and strategies to optimize the diagnosis, treatment, and management of CP-CML. Engage directly with leading experts through multiple discussion sessions, where you can present your questions and real-world cases for personalized guidance. Navigate the evolving evidence for individualized frontline CP-CML treatment, optimize response monitoring strategies, and gain insights into current recommendations for managing treatment intolerance and failure. This symposium promises to enrich your understanding of CP-CML, challenge your clinical acumen, and empower you to apply the latest evidence in your practice. Contribute to thought-provoking dialogues on CP-CML, shaping the discourse and enhancing collective expertise in this critical field.
Chair:
Jerald Radich, MD
Fred Hutchinson Cancer Center
Speakers:
Neil P. Shah
University of California
B. Douglas Smith, MD
Johns Hopkins University School of Medicine
Contact:
Ishana Fleurant
, Clinical Care Options, LLC.
Email: [email protected]
Registration for Virtual Program
Accelerating Evidence Into Practice: Leveraging QI-Driven Insights and Practical Tools to Integrate Bispecific Antibodies Into Care for Patients With R/R DLBCL and FL
This program is supported by PRIME Education. There is no fee to participate. This activity is supported by an educational grant from Genmab US, Inc.
11:00 a.m. - 2:00 p.m. Eastern time
OCCC - W331
Join lymphoma experts as they take a deep dive into the latest clinical evidence and practical considerations for evidence-based integration of bispecific antibodies (bsAbs) into treatment plans for patients with DLBCL and FL. Featuring patient testimonials to provide patient perspectives on receiving bsAbs and discuss treatment preferences, the expert faculty will guide the audience through nuances for navigating step-up dosing schedules and individualized treatment decision-making while reviewing the latest clinical evidence and guideline recommendations. Learners will have access to established resources from prior initiatives with bsAb therapy in DLBCL/FL to support optimal administration and management. Additionally, Throughout the program, faculty will engage the onsite and virtual attendees through gamified interactive polling and participate in a live Q&A. Altogether, this satellite symposium will harness real-world testimonials and clinic-focused resources to deepen the impact of the education and support providers in enhancing the care and delivery of bsAbs for DLBCL and FL.
Chair:
Paolo Strati, MD
The University of Texas MD Anderson Cancer Center
Speaker:
Caron Jacobson, MD, MMSc
Dana Farber Cancer Institute
Contact:
Eryn Litvinas
, PRIME Education
Email: [email protected]
Registration for Virtual Program
Advancing Hemophilia Care—Uniting Expert Insights and Community Voices to Shape the Future of Non-Factor Replacement Therapy
This program is supported by Novo Nordisk. Provided by Clinical Care Options, LLC.
11:00 a.m. - 2:00 p.m. Eastern time
Hyatt - Orlando Ballroom
This session will be live streamed on hematology.org during the scheduled time.
Join CCO for an engaging symposium focused on advancing hemophilia care through non-factor replacement therapies. This dynamic event combines expert panel discussions, real-world case challenges, and insights from patients and community HCPs to explore the latest data on novel therapies including fitusiran, concizumab, marstacimab, and Mim8. Through interactive polling and audience Q&A, attendees will gain practical guidance on integrating these therapies into personalized care strategies for patients with moderate to severe hemophilia A and B. Discover how to navigate evolving safety profiles, improve joint health outcomes, and tailor treatment based on patient needs and preferences. This symposium offers a comprehensive view of current challenges, cutting-edge solutions, and future directions in hemophilia management, equipping you with actionable insights to improve clinical practice.
Chair:
Steven Pipe, MD
University of Michigan
Speakers:
Stacy Croteau, MD
Harvard Medical School
Kristin Maher
University of Washington
Contact:
Ishana Fleurant
, Clinical Care Options, LLC.
Email: [email protected]
Registration for Virtual Program
Advancing Outcomes in Lymphoma Care: A Master Class on Integrating the CAR T-Cell Therapies into Clinical Practice
This program is supported by Bristol Myers Squibb and Kite Pharma, Inc. Provided by Clinical Care Options, LLC.
11:00 a.m. - 2:00 p.m. Eastern time
Hyatt - Regency Ballroom OPQ
This session will be live streamed on hematology.org during the scheduled time.
Join CCO for an engaging symposium exploring the latest advancements in CAR T-cell therapy for relapsed/refractory (R/R) lymphomas. This dynamic event features expert-led discussions, real-world case challenges, and interactive polling to examine the expanding role of CAR T-cell therapies across B-cell lymphoma subtypes. Gain practical insights into patient selection, referral pathways, and coordination of care, along with strategies to manage acute and chronic toxicities such as CRS and ICANS. Learn how to educate patients and caregivers, implement survivorship planning, and optimize long-term outcomes. The symposium also highlights next-generation CAR T-cell innovations, including off-the-shelf products and combination strategies. Engage directly with faculty during live Q&A sessions, apply knowledge through interactive cases, and leave equipped to enhance care for patients receiving CAR T-cell therapy.
Chair:
Stephen Ansell, MD, PhD
Mayo Clinic Comprehensive Cancer Center
Speakers:
Jeremy Abramson, MD
Harvard Medical School
Michael D. Jain
Moffitt Cancer Center
Patrick Connor Johnson, MD
Harvard Medical School
David Maloney
University of Washington
Contact:
Ishana Fleurant
, Clinical Care Options, LLC.
Email: [email protected]
Registration for Virtual Program
Cases & Conversations™: Real-World Insights on Advances in the Management of Myeloproliferative Neoplasms: How the Experts Apply the Latest Developments to Clinical Practice
This program is supported by Geron Corporation, Incyte Corporation, PharmaEssentia, and Takeda.
11:00 a.m. - 2:00 p.m. Eastern time
OCCC - W224ABEF
The live portion of this curriculum will be presented as a 2.5-hour Friday Satellite Symposium (FSS) held prior to the 2025 ASH Annual Meeting. This satellite program will bring together 4 clinical experts to review the latest data regarding the management of MPNs, with short didactic presentations supplemented by panel discussions of challenging case scenarios. To further enhance the integration of recent data into practice, the program will feature an interactive question-and-answer session between the faculty and attendees to emphasize areas of educational need, highlight areas of debate, and illustrate the application of new data in defined clinical situations.
Chair:
Naveen Pemmaraju, MD
Executive Director, MDACC Network, The University of Texas MD Anderson Cancer Center
Speaker:
Angela Fleischman, MD, PhD
University of California, Irvine, School of Medicine
Contact:
Elijah Anseaume
, Physicians’ Education Resource®, LLC (PER)
Email: [email protected]
Registration for Virtual Program
Cases from the Community: Investigators Discuss Available Research Guiding the Selection of Therapy for Patients with Chronic Lymphocytic Leukemia
This program is supported by educational grants from Abbvie Inc., AstraZeneca Pharmaceuticals LP, BeOne, Bristol Myers Squibb, and Lilly.
11:00 a.m. - 2:00 p.m. Eastern time
Hyatt - Regency TUV
This session will be live streamed on hematology.org during the scheduled time.
This 2-hour CME-accredited activity – offered to both in-person and virtual attendees – will focus on the management of patients with chronic lymphocytic leukemia (CLL). Four clinical investigators will serve as the faculty and Dr Neil Love, RTP president, will moderate. Prior to the meeting, Research To Practice (RTP) will video record interviews with 3 general medical oncologists/hematologists (GMOs) who will present challenging CLL cases from their practices. To begin each of the 4 meeting modules, excerpts from the GMO interviews will be broadcast and the panelists will discuss the optimal management of the patients presented. 1 faculty member will then deliver a formal presentation reviewing available research related to the cases. Attendees will be able to submit questions and cases of their own, a number of which will be incorporated into the discussion. Pre-registration is advised as seating is limited.
Chair:
Neil Love, MD
Research To Practice
Speakers:
Matthew S Davids, MD
Dana-Farber Cancer Institute
Bita Fakhri, MD, MPH
Stanford University
Constantine S. Tam, MD,MBBS
Monash University
Jennifer A. Woyach, MD
The Ohio State University
Contact:
Sylvia Eriksen
, Research To Practice
Email: [email protected]
Registration for Virtual Program
From Indolent to Aggressive: Case-Based Strategies Across the Spectrum of Systemic Mastocytosis
This program is supported by an independent educational grant from Blueprint Medicines Corporation and provided by Integritas Communications.
11:00 a.m. - 2:00 p.m. Eastern time
OCCC - W224CDGH
Systemic mastocytosis (SM) is a complex and often misdiagnosed condition that can affect multiple organ systems and cause symptoms ranging from anaphylaxis to bone pain and gastrointestinal distress. This interactive Case-in-Point™ CME symposium will feature real-world case discussions, audience polling, and expert insights to help clinicians navigate the challenges of diagnosing and managing both nonadvanced and advanced SM. Expert faculty will review updated diagnostic criteria, emerging and FDA-approved treatment strategies, and provide practical guidance on monitoring treatment response, addressing persistent symptoms, and engaging patients in shared decision-making. Whether you are new to SM care or looking to refine your approach, this session will enhance your confidence and equip you with practical strategies to optimize care for patients across the SM spectrum.
Pre-registration is advised as seating is limited.
Speakers:
Brian J. Chernak, MD
Leukemia Specialist, Memorial Sloan Kettering Cancer Center
Matthew P. Giannetti
Associate Director, Brigham and Women’s Hospital Mastocytosis Center
Tsewang Tashi, MD
Associate Professor, Division of Hematology and Hematologic Malignancies, University of Utah, Huntsman Cancer Institute
Contact:
Shannon Stevenson
, Integritas
Email: [email protected]
Registration for Virtual Program
Medical Crossfire®: Advances in ALL Management Across the Patient Spectrum: Integrating Innovation and Precision Care
This program is supported by Servier, Jazz, Amgen, and Autolus Inc.
11:00 a.m. - 2:00 p.m. Eastern time
OCCC - Tangerine Ballroom F1
This session will be live streamed on hematology.org during the scheduled time.
The live portion of this curriculum will be presented as a 2.5-hour Friday Satellite Symposium (FSS) held prior to the 2025 ASH Annual Meeting.
This satellite program will bring together four clinical experts to review the latest data regarding the management of patients with ALL, with short didactic presentations supplemented by panel discussions of challenging case scenarios.
The program will bring to the patient voice to the forefront, with panel discussions between the clinical experts and a patient advocate to review practical measures bridge disparities in the treatment of ALL.
Chair:
Elias Jabbour
The University of Texas MD Anderson Cancer Center
Speakers:
Hagop Kantarjian, MD
The University of Texas MD Anderson Cancer Center
Aaron C. Logan, MD, PhD
University of California, San Francisco
Rob Pieters, MD, PhD, MSc
Princess Máxima Center for Pediatric Oncology
Claire Roddie, MD, PhD
University College London (UCL) Hospitals
Contact:
Elijah Anseaume
, Physicians’ Education Resource®, LLC (PER)
Email: [email protected]
Registration for Virtual Program
Medical Crossfire®: Experts Debate the Hottest Topics in AML – FLT3, IDH1/2, KMT2Ar, NPM1, Secondary AML, Maintenance, Novel Combinations, and Emerging Therapies
This program is supported by Kura Oncology, Inc., Rigel Pharmaceuticals, Inc. and Taiho Oncology Inc.
11:00 a.m. - 2:00 p.m. Eastern time
OCCC - Tangerine Ballroom F2
This session will be live streamed on hematology.org during the scheduled time.
CME - Certified Hybrid Satellite Symposium:
The live portion of this curriculum will be presented as a 3.0-hour Friday Satellite Symposium (FSS) held prior to the 2025 ASH Annual Meeting.
This satellite program will bring together four clinical experts to review the latest data regarding the management of AML, with short didactic presentations supplemented by panel discussions of challenging case scenarios.
The program will bring to the patient voice to the forefront, with panel discussions between the clinical experts and a patient advocate to review practical measures bridge disparities in the treatment of AML.
To further enhance the integration of recent data into practice, the program will feature an interactive polling and question-and-answer sessions between the faculty and attendees to emphasize areas of educational need, highlight areas of debate, and illustrate the application of new data in defined clinical situations.
Chair:
Naval Daver, MD
The University of Texas MD Anderson Cancer Center
Speakers:
Daniel Pollyea, MD
Clinical Director of Leukemia Services, University of Colorado
Gail J Roboz
Professor of Medicine, Director of the Clinical and Translational Leukemia Program, Weill Medical College of Cornell University
Amer M. Zeidan, MD
Yale University
Contact:
Elijah Anseaume
, Physicians’ Education Resource®, LLC (PER)
Email: [email protected]
Registration for Virtual Program
Rare Clinical Spotlight: Exploring Castleman Disease, Cold Agglutinin Disease, and Acute Intermittent Porphyria
This program is supported by Recordati Rare Diseases.
11:00 a.m. - 2:00 p.m. Eastern time
Hyatt - Plaza Int'l HIJK
This session will be live streamed on hematology.org and the ASH Virtual Meeting Platform during the scheduled time.
Join us for this unique 90-minute symposium which will showcase three rare hematologic diseases, Castleman disease (CD), cold agglutinin disease (CAD), and acute intermittent porphyria (AIP), with the shared expertise of 6 faculty that treat these rare diseases! Faculty for each disease area, will present compelling cases with interactive polling questions as a platform to weave in clinical decision-making points for improving patient outcomes. Learn what drives these diseases by understanding their pathophysiology and subsequently how to recognize signs and symptoms to properly diagnose these rare patients. Current and emerging treatment options will be presented, and faculty will disseminate key efficacy and safety data to help you understand how to choose optimal treatment approaches for patients. Take advantage of this opportunity to engage with and ask these expert faculty your important questions and walk away with more knowledge for treating patients with these diseases.
Speakers:
Catherine Broome, MD
Georgetown University
Angelika Erwin, MD
Cleveland Clinic
Sudipto Mukherjee, MD, PhD, MPH
Cleveland Clinic Taussig Cancer Institute
Ariela Noy, MD
Memorial Sloan Kettering Cancer Center
Bruce Wang, MD
University of California, San Francisco
Ilene Weitz, MD
Keck School of Medicine of USC
Contact:
Carolyn Ciaramella
, MedscapeLIVE
Email: [email protected]
Registration for Virtual Program
Tailoring Bispecific Antibodies to Individualize R/R Follicular Lymphoma Care: A Case-Based Discussion
This program is supported by Genmab US, Inc. and AbbVie.
11:00 a.m. - 2:00 p.m. Eastern time
OCCC - W311EFGH
This session will be live streamed on hematology.org and the ASH Virtual Meeting Platform during the scheduled time.
This 90-minute symposium will feature 2 expert hematologists/oncologists and a patient advocate from the Lymphoma Coalition as they explore the evolving role of bispecific antibodies in treating refractory/relapsed follicular lymphoma (R/R FL). Through engaging case discussions and expert presentations, you will gain insights into treatment selection, adverse event management, and overcoming logistical challenges. Learn best practices for integrating these innovative agents into patient care while emphasizing the importance of patient-centered strategies.
Chair:
Matthew A. Lunning, DO, FACP
University of Nebraska Medical Center
Speakers:
Natacha Bolaños
Lymphoma Coalition
Chan Cheah, MBBS, DMSc
Breakthrough Haematology
Contact:
Carolyn Ciaramella
, MedscapeLIVE
Email: [email protected]
Registration for Virtual Program
Targeted Therapies in R/R PCNSL: New Frontiers in Treatment and Management
This program is supported by Deciphera, a member of ONO Pharma.
11:00 a.m. - 2:00 p.m. Eastern time
Hyatt - Plaza Int'l DEFG
This session will be live streamed on hematology.org and the ASH Virtual Meeting Platform during the scheduled time.
Do you know the latest advancements in primary central nervous system lymphoma (PCNSL)? Join expert faculty in the field of PCNSL for an in-depth look at relapsed/refractory (R/R) disease. This program will review the latest clinical trial data and novel therapeutic strategies. A unique Expert Voices discussion will highlight the clinical implications of these advancements for the evolving management of R/R PCNSL.
Chair:
Christopher DeAngelo, MD
University of Nebraska Medical Center
Speakers:
Ayushi Chauhan, MD
The University of Texas at MD Anderson Cancer Center
Ashley Sumrall, MD, FACP, FASCO
Atrium Health
Contact:
Carolyn Ciaramella
, MedscapeLIVE
Email: [email protected]
Registration for Virtual Program
The Growing Role of CAR T-Cell Therapy in Multiple Myeloma: New Data on Earlier Lines of Therapy, Expanding Access to Treatment
This program is supported by educational grants from Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, Bristol Myers Squibb, Kite Pharma, Inc., Arcellx, Inc., and Legend Biotech.
11:00 a.m. - 2:00 p.m. Eastern time
OCCC - W230
This session is in-person and does not have a virtual component. Please contact the Managing Company Contact with questions.
This live symposium will highlight cutting-edge clinical data and research findings associated with CAR T-cell therapy in multiple myeloma (MM). Experts will deliver in-depth analyses of the latest developments, focusing on real-world clinical implications, and attendees will learn about the most current and impactful data that will enhance their ability to use CAR T-cell therapies for MM. A series of brief patient case studies will set the stage and launch faculty presentations and panel discussions. The faculty will offer their interpretations of the data, share practical insights, and address potential challenges in applying the findings to patient care. Attendees will use mobile technology to participate in case studies, submit questions to faculty, and explore how new evidence can be translated into improved clinical outcomes. This combination of data presentation and faculty feedback contributes to deeper engagement and encourages practical application of learnings.
Chair:
Luciano Jose Costa, MD, PhD
University of Alabama at Birmingham
Speakers:
Michael R. Bishop, MD
The David and Etta Jonas Center for Cellular Therapy University of Chicago Medicine
Binod Dhakal, MD, MS
Medical College of Wisconsin
Contact:
Kim DiGuiseppe
, Haymarket Medical Education
Email: [email protected]
Achieving Comprehensive Care for Chronic Immune Thrombocytopenia: Exploring Emerging Therapies to Address Patient-centric Hematological and Non-Hematological Outcomes
This program is supported by an educational grant from Sanofi. This activity is jointly provided by AKH Inc., Advancing Knowledge in Healthcare and Catalyst Medical Education, LLC.
3:00 p.m. - 6:00 p.m. Eastern time
Hyatt - Regency Ballroom R
This session is in-person and does not have a virtual component. Please contact the Managing Company Contact with questions.
Up to 20% of pediatric patients and up to 70% of adult patients with immune thrombocytopenia have chronic disease, persisting for at least 12 months. Though available treatment options have seen some success, they are limited in their ability to address the underlying autoimmune platelet destruction etiology of ITP and often possess negative risk profiles. As a result, patients often live with uncontrolled hematological and non-hematological disease burden, including fatigue and cognitive impairment. Emerging therapies, such as Bruton’s tyrosine kinase inhibitors (BTKi), FcRN blockers, and other strategies, may offer more effective, durable, and safer treatment options to address the multi-faceted burden of ITP. Ensuring patients can access these novel therapies requires efforts to remain up-to-date with their supporting scientific data and understand principles for integrating treatments into practice. Through a dynamic format that integrates evidence-based presentations, panel discussions, and clinical cases, expert faculty participating in this symposium will bring evolving science to life and provide clinical insights to evolving strategies to address hematological and non-hematological ITP manifestations and improve the patient experience.
Learning objectives:
o Recognize unmet hematological, quality of life, and long-term health needs of individual living with chronic ITP
o Evaluate the MoA and clinical data on BTKi treatments, and other novel disease-targeting treatments, for chronic ITP, considering hematological, safety, and patient-reported outcomes
o Propose practical strategies that support improved screening and assessment for fatigue, cognitive impairment, and other health related QoL outcomes in chronic ITP
o Integrate patient-centered strategies into chronic ITP management plans that foster early intervention to address uncontrolled disease, considering current and emerging therapy options, and support shared decision-making in the second-line treatment setting
Chair:
David Kuter, MD, DPhil
Massachusetts General Hospital
Speakers:
Nicola Cooper, MD, FRCP, FRCPath, MA
Imperial College Healthcare; NHS Trust
Cindy Neunert, MD
Columbia University Irving Medical Center
Contact:
Margaret Catherine Walker
, Catalyst Medical Education
Email: [email protected]
Acute Hepatic Porphyria: Bridging Gaps for Better Diagnosis and Management
This program is supported by Alnylam U.S., Inc.
3:00 p.m. - 6:00 p.m. Eastern time
Hyatt - Plaza Int'l HIJK
This session will be live streamed on hematology.org and the ASH Virtual Meeting Platform during the scheduled time.
Acute hepatic porphyria (AHP) is a rare, debilitating disease with significant diagnostic and management challenges, making provider education critical. This symposium will feature 3 expert faculty in a dynamic “Learn, Discuss, Ask” format designed to maximize engagement and knowledge exchange. Each segment begins with a focused presentation, followed by a case-based panel discussion, and concludes with audience Q&A. Participants will gain a deeper understanding of AHP, from disease awareness and diagnostic challenges to evolving management strategies and real-world applications in care. Faculty will explore the etiology, pathophysiology, clinical presentations, and unmet needs associated with AHP, while also reviewing therapeutic advances and treatment mechanisms, monitoring approaches and safety considerations, as well as future directions, including clinical trial data.
Chair:
Brendan M. McGuire, MD
University of Alabama at Birmingham
Speakers:
Rebecca Karp, MD
Massachusetts General Hospital
Akshata Moghe, MD
University of Texas Health Science Center
Contact:
Carolyn Ciaramella
, MedscapeLIVE
Email: [email protected]
Registration for Virtual Program
Bridging the Gaps in CAR T-Cell Therapy for Hematological Malignancies: Expert Guidance, Clinical Experience and Increased Access
This program is supported by Roswell Park Alliance Foundation and Bristol Myers Squibb.
3:00 p.m. - 6:00 p.m. Eastern time
OCCC - W230
This session is in-person and does not have a virtual component. Please contact the Managing Company Contact with questions.
Chimeric antigen receptor (CAR) T cell therapy has reshaped the treatment landscape for B-cell malignancies, yet major clinical and implementation challenges persist.
This symposium addresses critical unmet needs in the field:
- Optimizing CAR T cells in real-world practice
- Sequencing therapies
- Managing post-relapse scenarios
- Understanding resistance biology
- Expanding access to underserved populations
Given the rapid evolution of therapies and shifting treatment paradigms, there is an urgent need to equip clinicians and researchers with expert guidance on how to navigate these complex decisions and translate new data into patient-centered care.
Chairs:
Marco Davila, MD, PhD
Roswell Park Comprehensive Cancer
Renier Brentjens
Deputy Director, Chair, Department of Medicine, Roswell Park Comprehensive Cancer Center
Speakers:
Julio C Chavez, MD, MS
Sr. Associate Consultant, Lymphoma Program Lead, Mayo Clinic
Marco Davila, MD, PhD
Roswell Park Comprehensive Cancer
Francisco Hernandez-Ilizaliturri, MD
Director of Lymphoma Research and Lymphoma Translational Research Lab, Roswell Park Comprehensive Cancer Center
Shernan Holtan, MD
Chief, Blood and Marrow Transplantation Section, Roswell Park Comprehensive Cancer Center
Frederick Locke, MD
Chair, Blood and Marrow Transplant and Cellular Immunotherapy, Moffitt Cancer Center
Contact:
Ashley Snowden
, Roswell Park Comprehensive Cancer Center
Email: [email protected]
BRINGING EMERGING TREATMENTS TO ALL PATIENTS: Strategies for Implementing T-cell Redirection Therapies in Community Oncology Practices
This program is supported by Amgen, Pfizer Oncology and Indy Hematology Education Inc.
3:00 p.m. - 6:00 p.m. Eastern time
OCCC - Valencia Room W415BC
Innovative immune effector therapies, including CAR T-cell and bi-specific antibody treatments, have transformed cancer care but remain largely inaccessible to community oncology practices. This symposium is dedicated to bridging this gap by establishing the necessary infrastructure, protocols, and training to safely and effectively administer these lifesaving therapies in community settings. By promoting equitable access, fostering clinical trial participation, and supporting diverse patient populations, we aim to reduce disparities and expand the reach of modern cellular therapies.
Chair:
Ruemu Ejedafeta Birhiray, MD
Indy Hematology Education Inc.
Speakers:
Ralph Vincent Boccia, MD
The Center for Cancer and Blood Disorders
Tara Graff, DO,MS
Mission Cancer and Blood
Nikhil Munshi, MD
Dana-Farber Cancer Institute
Tycel Phillips, MD, FASCO
Associate Professor, Division of Lymphoma, Department of Hematology and Hematopoietic Cell Transplantation; City of Hope Comprehensive Cancer Center
Richard Stone, MD
Dana-Farber Cancer Institute
Contact:
Sam Ranger
, Indy Hematology Education Inc.
Email: [email protected]
Registration for Virtual Program
Cases and Conversations™: Optimizing Patient Outcomes in Pediatric/AYA and Adult ALL/LBL With Asparaginase Therapies and Combinations
This program is supported by Servier Pharmaceuticals LLC.
3:00 p.m. - 6:00 p.m. Eastern time
OCCC - Tangerine Ballroom F1
This session will be live streamed on hematology.org during the scheduled time.
The live portion of this curriculum will be presented as a 2.5-hour Friday Satellite Symposium (FSS) held prior to the 2025 ASH Annual Meeting.
This satellite program will bring together four clinical experts to review the latest data regarding the management of CML, with short didactic lectures supplemented by panel discussions of pertinent clinical challenges, emerging treatment strategies, and real-world applications of current guidelines.
To further enhance the integration of recent data into practice, the program will feature an interactive question-and-answer session between the faculty and attendees to emphasize areas of educational need, highlight areas of debate, and illustrate the application of new data in defined clinical situations.
Chairs:
Daniel J Deangelo, MD, PhD
Dana-Farber Cancer Institute
Daniel J Deangelo, MD, PhD
Dana-Farber Cancer Institute
Speakers:
Shira Dinner, MD
Northwestern University
Stephen P. Hunger, MD
Children's Hospital of Philadelphia
Jae Park, MD
Memorial Sloan Kettering Cancer Center
Contact:
Elijah Anseaume
, Physicians’ Education Resource®, LLC (PER)
Email: [email protected]
Registration for Virtual Program
Cracking the Code: Menin Inhibitors and the Next Frontier in AML Treatment
This program is supported by PRIME Education. There is no fee to participate. This activity is supported by an educational grant from Kura and Syndax.
3:00 p.m. - 6:00 p.m. Eastern time
OCCC - W331
Join acute myeloid leukemia (AML) experts as they take a deep dive into the latest evidence from clinical trials for new and emerging menin inhibitors for AML. Specifically, faculty will guide the audience through various menin inhibitor topics, including (1) the biologic rationale and implications of KMT2A rearrangements and NPM1 mutations for AML prognosis, (2) clinical evidence supporting guideline recommendations for menin inhibitors in AML treatment plans and the potential place in therapy for emerging agents, (3) nuances of treatment strategy including relation to transplant, dosing and administration, (4) appropriate genetic tests and the implications on treatment decision-making, and (5) mitigation, monitoring and managing unique adverse events of menin inhibitor therapies. Additionally, throughout the program, faculty will engage the onsite and virtual attendees through gamified interactive polling and participate in a live Q&A. Furthermore, to support faculty in synthesizing the latest data, an AML Clinical Trial Pocket Guide will be available providing a concise overview of novel menin inhibitors and combinations in clinical trials. Altogether, this satellite symposium will feature expert discussion and case-based learning designed to decode the latest clinical evidence on menin inhibitors to optimize treatment of patients with R/R AML.
Chair:
Joshua Zeidner, MD
University of North Carolina School of Medicine
Speaker:
Justin Watts, MD
University of Miami/Sylvester Comprehensive Cancer Center (SCCC)
Contact:
Eryn Litvinas
, PRIME Education
Email: [email protected]
Registration for Virtual Program
Expert Second Opinion: Investigators Discuss the Optimal Management of Patients with Myelofibrosis and Systemic Mastocytosis
This program is supported by educational grants from Blueprint Medicines, Bristol Myers Squibb, GSK, and Incyte Corporation.
3:00 p.m. - 6:00 p.m. Eastern time
Hyatt - Regency TUV
This session will be live streamed on hematology.org during the scheduled time.
This 2-hour CME-accredited activity – offered to both in-person and virtual attendees – will focus on the management of patients with myelofibrosis (MF) and systemic mastocytosis (SM). 5 clinical investigators will serve as the faculty and Dr Neil Love, RTP president, will moderate. Prior to the meeting, Research To Practice (RTP) will record interviews with 3 additional investigators who will present interesting teaching cases from their practices of patients with MF. To begin each of the 5 meeting modules, excerpts from the recorded case interviews will be broadcast. The panelists will then discuss the optimal management of the patients presented. Each faculty member will then deliver a formal presentation reviewing available research. Attendees will be able to submit questions and cases of their own, a number of which will be incorporated into the discussion. Pre-registration is advised as seating is limited.
Chair:
Neil Love, MD
Research To Practice
Speakers:
Claire Harrison, DM
Guy’s and St Thomas’ NHS Foundation Trust
Andrew T Kuykendall, MD
Moffitt Cancer Center
Stephen Oh, MD, PhD
Washington University School of Medicine
Jeanne Palmer
Vice Chair, and Section Chief for Hematology, Program Director for the Blood and Marrow Transplant Program, Mayo Clinic
Raajit Rampal, MD, PhD
Memorial Sloan Kettering Cancer Center
Contact:
Sylvia Eriksen
, Research To Practice
Email: [email protected]
Registration for Virtual Program
Filling in the Gaps in Hemophilia Guideline Recommendations: Evidence-Based Strategies to Optimize Patient-Relevant Outcomes
This program is supported by an independent medical education grant from Sanofi.
3:00 p.m. - 6:00 p.m. Eastern time
OCCC - Valencia Room W415A
This session is in-person and does not have a virtual component. Please contact the Managing Company Contact with questions.
Emerging therapies have the potential to transform care for patients with hemophilia, a rare chronic bleeding disorder in which impaired coagulation leads to spontaneous and traumatic bleeding. This CME-approved live panel discussion will help clinicians frame recent hemophilia guidelines into clinical practice and provide recommendations on the use of new therapies in hemophilia patients of all ages. Case studies will be used to review recent clinical trial data and examine the pros and cons of treatment options, including novel clotting factor concentrates, factor VIII mimetics, rebalancing agents, and gene therapies. Hemophilia panel members will use polling to engage the audience in a discussion of how to manage hemophilia A and B through shared decision making at all stages of their patients’ lives.
Chairs:
Allison Wheeler, MD, MSCI
Scientific Director, Washington Center for Bleeding Disorders, University of Washington School of Medicine
Lynn Malec, MD, MSc
Versiti Blood Research Institute
Speakers:
Shannon L. Meeks, MD
Professor of Pediatrics, Aflac Cancer and Blood Disorders Center, Emory University
Michael Recht
Yale University
Annette von Drygalski
Director, Center for Bleeding and Clotting Disorders, University of California, San Diego
Contact:
Madelyne Fabrizio
, i3 Health
Email: [email protected]
Medical Crossfire®: Navigating GVHD Prophylaxis, Acute and Chronic Care - Targeted Strategies to Elevate Patient Outcomes
This program is supported by Orca Bio.
3:00 p.m. - 6:00 p.m. Eastern time
OCCC - Tangerine Ballroom F2
This program convenes a panel of world-renowned expert faculty in GVHD to tackle pressing clinical issues. The panel offers participants invaluable clinical pearls, practical strategies, and insights from leaders in the field. The dynamic format encourages active engagement, challenging participants to critically evaluate their practices and apply the latest evidence to improve patient care.
Chair:
Corey Cutler, MD,FRCPC,MPH
Dana-Farber Cancer Institute
Speakers:
Amin Alousi, MD
The University of Texas MD Anderson Cancer Center
Mehdi Hamadani, MD
Medical College of Wisconsin
Anna Sureda Balarí, MD,PhD
Institut Català d'Oncologia - Hospital Duran i Reynals
Contact:
Elijah Anseaume
, Physicians’ Education Resource®, LLC (PER)
Email: [email protected]
Registration for Virtual Program
Myeloma Myth Busters: Investigating the Now, Soon, and Future Clinical Implications of CELMoDs
This program is supported by Bristol Myers Squibb. Provided by Clinical Care Options, LLC.
3:00 p.m. - 6:00 p.m. Eastern time
Hyatt - Regency Ballroom OPQ
This session will be live streamed on hematology.org during the scheduled time.
Join CCO for an interactive, case-based symposium exploring the evolving role of CELMoD therapy in multiple myeloma (MM). Through a unique “Two Truths and a Myth” gameshow format, expert faculty will unpack key mechanistic differences between CELMoDs and IMiDs, review pivotal trial data for iberdomide and mezigdomide, and discuss the clinical implications of MRD-negative complete response as a surrogate endpoint. Participate in dynamic faculty Q&A sessions and real-world patient case challenges that highlight how CELMoDs may be integrated into near-future treatment paradigms and clinical trials. Prepare for the next wave of innovation in MM care.
Chair:
Niels W.C.J. Van De Donk
Amsterdam University Medical Center
Speakers:
Jesús Berdeja, MD
Greco-Hainsworth Centers for Research
Amrita Krishnan, MD
City of Hope Cancer Center
Contact:
Ishana Fleurant
, Clinical Care Options, LLC.
Email: [email protected]
Registration for Virtual Program
PER® Tumor Board: Charting a New Course in the Treatment of Newly Diagnosed Multiple Myeloma
This program is supported by Sanofi.
3:00 p.m. - 6:00 p.m. Eastern time
OCCC - Tangerine Ballroom F3-4
This session will be live streamed on hematology.org during the scheduled time.
This satellite program will bring together four clinical experts to review real-world cases that synthesize recent data from landmark trials of new approaches for the management of NDMM into practical insights for clinicians to implement in routine practice. To further enhance the integration of recent data into practice, the program will feature an interactive question-and-answer session between the faculty and attendees to emphasize areas of educational need, highlight areas of debate, and illustrate the application of new data in defined clinical situations.
Chair:
Ajai Chari, MD
University of California, San Francisco
Speakers:
María-Victoria Mateos, MD, PhD
University of Salamanca
Mohamad Mohty, MD, PhD
Saint-Antoine Hospital Sorbonne University
Contact:
Elijah Anseaume
, Physicians’ Education Resource®, LLC (PER)
Email: [email protected]
Registration for Virtual Program
Personalizing Relapsed/Refractory DLBCL With Bispecific Antibody Therapy: A Case-Based Discussion
This program is supported by Genmab US, Inc. and AbbVie.
3:00 p.m. - 6:00 p.m. Eastern time
OCCC - W311EFGH
This unique interactive program is designed to enhance your clinical approach to refractory/relapsed diffuse large B-cell lymphoma (R/R DLBCL). Our expert faculty, including a patient advocate from the Lymphoma Coalition, will utilize real-world case studies to highlight best practices in personalizing DLBCL care with bispecific antibodies. Stay updated on advancements in R/R DLBCL treatment.
Chair:
Joshua Brody, MD
Icahn School of Medicine at Mount Sinai
Speakers:
Liz Brém, MD
UCI Health
Lorna Warwick, BA
Lymphoma Coalition
Contact:
Carolyn Ciaramella
, MedscapeLIVE
Email: [email protected]
Registration for Virtual Program
Staying in the Lead: Navigating the Changing Course of Sickle Cell Disease Management —A CME COMPETE™: SCD Edition
This program is supported by Novo Nordisk Inc. Provided by Integritas Communications.
3:00 p.m. - 6:00 p.m. Eastern time
OCCC - W224CDGH
This session will be live streamed on hematology.org during the scheduled time.
Sickle cell disease (SCD) presents a lifelong clinical burden with significant variability across patients. It is a leading cause of mortality, morbidity, and health disparities, yet remains considerably undertreated. Current therapeutic innovation is rapidly shifting and so must the treatment paradigm. This symposium will use a Test–Teach–Compete format to engage attendees in a high-impact learning experience focused on the evolving landscape of SCD care. Through a blend of didactic teaching, interactive case challenges, and dynamic gamification elements, expert faculty will guide participants through a progression of key topics—from foundational pathophysiology and lifelong disease burden to the limitations of traditional treatments and the promise of curative and disease-modifying options, including FDA-approved gene-editing treatments and emerging pyruvate kinase activators. Join us for an engaging, case-driven session designed to help transform how we approach the care of patients living with SCD.
Speakers:
Lakiea Bailey, PhD
Director, Sickle Cell Consortium; Patient Advocate, Educator, Research Scientist
Modupe Idowu, MD
Director, Hematology/Oncology, UTHealth
Nirmish Shah, MD
Associate Professor, Hematology, Duke University
Contact:
Shannon Stevenson
, Integritas Communications
Email: [email protected]
Registration for Virtual Program
Visualizing Novel Pathways to Optimizing Care for Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH)
This program is supported by Novartis Pharmaceuticals.
3:00 p.m. - 6:00 p.m. Eastern time
OCCC - W224ABEF
This session will be live streamed on hematology.org during the scheduled time.
Paroxysmal nocturnal hemoglobinuria (PNH) is a rare genetic hematologic disorder that stems from deficient proteins that mediate the complement pathway. [DeZern 2015] Unregulated complement activity leads to its hallmark manifestations of hemolytic anemia, bone marrow failure, and elevated risk of thrombosis. The clinical symptoms vary considerably between affected individuals. Patients may present with unexplained hemolytic anemia, fatigue, jaundice, and red/pink/dark urine, while others experience headaches, dysphagia, scleral icterus, or confusion. Approximately 10-20 people per million worldwide live with PNH. [Cancado 2021] Although it can occur at any age, PNH is often diagnosed between the ages of 30 to 40. [Hill 2017]; [Schrezenmeier 2020].
Before the availability of effective treatments, the median survival was just 15 to 20 years, with thrombosis as the leading cause of death. [Bektas 2020a] The development of targeted complement inhibitors has transformed outcomes for patients with PNH, enabling patients to achieve life expectancies similar to age-matched controls. [Bodo 2023]
Speakers:
Caroline Piatek, MD
University of Southern California
Jamile Shammo, MD, FASCP, FACP
Northwestern University Feinberg School of Medicine
Contact:
Kelly McGregor
, PER
Email: [email protected]
Registration for Virtual Program
EXPERT SECOND OPINION: Investigators Discuss the Role of Novel Treatment Approaches in the Care of Patients with Follicular Lymphoma and Diffuse Large B-Cell Lymphoma
This program is supported by educational grants from ADC Therapeutics, Genentech, a member of the Roche Group, Incyte Corporation, and Pfizer Inc.
7:00 p.m. - 10:00 p.m. Eastern time
Hyatt - Regency TUV
This session will be live streamed on hematology.org during the scheduled time.
This 2-hour CME-accredited activity – offered to both in-person and virtual attendees – will focused on the integration of novel approaches into the care of patients with DLBCL and FL. 5 investigators will serve as the faculty and Dr Neil Love, RTP president, will moderate. Prior to the meeting, Research To Practice (RTP) will record interviews with 3 additional investigators who will present interesting teaching cases from their practices of patients with DLBCL or FL treated with novel agents/strategies. To begin each of the 5 meeting modules, excerpts from the recorded case interviews will be broadcast. The panelists will then discuss the optimal management of the patients presented. 1 faculty member will then deliver a formal presentation reviewing available research. Attendees will be able to submit questions and cases of their own, a number of which will be incorporated into the discussion. Pre-registration is advised as seating is limited.
Chair:
Neil Love, MD
Research To Practice
Speakers:
Nancy L Bartlett, MD
Washington University School of Medicine
Matthew Matasar, MD, MS
Rutgers University
Loretta J Nastoupil
CommonSpirit Mercy Hospital
Grzegorz Nowakowski
Mayo Clinic
Pier Luigi Zinzani, MD, PhD
University of Bologna School of Medicine
Contact:
Sylvia Eriksen
, Research To Practice
Email: [email protected]
Registration for Virtual Program
Hot Topics in Myelofibrosis Management: Navigating the Latest Therapeutic Advances in Clinical Practice
This program is supported by educational grants from <span>Geron Corporation, Karyopharm Therapeutics, Kartos Therapeutics, and Sumitomo Pharma America, Inc. This activity is provided by PRIME Education. There is no fee to participate.</span>
7:00 p.m. - 10:00 p.m. Eastern time
OCCC - W331
Join myelofibrosis experts as they take a deep dive into the latest clinical evidence and practical considerations for various Hot Topics in myelofibrosis (MF) care. Bolstered by the latest clinical efficacy and safety data, educational material will focus on strategies to optimize guideline-aligned, patient-centered treatment selection, integrate evidence-based anemia management strategies into clinical practice, and synthesize the latest data on emerging therapies and their practice-changing potential. Specifically, faculty will guide the audience through various Hot Topics in the management of MF, including (1) individualizing JAK inhibitor selection, response monitoring, and sequencing, (2) assessing anemia symptoms and burden and optimizing treatment decisions to minimize transfusion requirements, (3) differentiating emerging MF therapies by MOA and clinical safety and efficacy data, and (4) understanding shifting treatment goals to achieve deeper clinical and molecular response. Additionally, throughout the program, faculty will engage the onsite and virtual attendees through gamified interactive polling and participate in a live Q&A. Altogether, this satellite symposium will feature expert discussion and case-based learning designed to support providers master the clinical data and adopt evidence-based strategies to deliver comprehensive MF care.
Chair:
John O. Mascarenhas, MD
Icahn School of Medicine at Mount Sinai
Speaker:
Lindsay Rein, MD
Duke University School of Medicine
Contact:
Eryn Litvinas
, PRIME Education
Email: [email protected]
Registration for Virtual Program
67th ASH Annual Meeting and exposition
Registration for ASH members, non-members, groups, exhibitors, and media is now open!